The primary objective of this study is to evaluate the efficacy of PG2 Injection 500 mg
versus placebo, administered intravenously within 3-6 hrs of stroke onset to patients with an
acute ischemic stroke, as determined by Modified Rankin Scale (mRS) score at Day 90.
The secondary objectives are as follows:
- To evaluate the efficacy of PG2 Injection 500 mg versus placebo as determined by Barthel
Index (BI) score at Day 90.
- To evaluate the efficacy of PG2 Injection 500 mg in reducing the risk of recurrent
stroke, cardiovascular events and death of all causes.
- To evaluate the safety of PG2 Injection 500 mg treatment
Phase:
Phase 2
Details
Lead Sponsor:
China Medical University Hospital
Collaborators:
Changhua Christian Hospital Cheng Hsin Rehabilitation Medical Center Chung Shan Medical University En Chu Kong Hospital Kaohsiung Medical University Kaohsiung Veterans General Hospital. Kuang Tien General Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Shin Kong Wu Ho-Su Memorial Hospital Taipei Medical University Shuang Ho Hospital Taipei Medical University WanFang Hospital Taipei Veterans General Hospital, Taiwan Tri-Service General Hospital